BioNTech to Host AI Day on October 1, 2025, in London.
PorAinvest
martes, 23 de septiembre de 2025, 6:49 am ET1 min de lectura
BNTX--
The event will take place at 9:00 AM EDT (3:00 PM CEST) and will be accessible via a live webcast. Participants can also access the slides and a recording of the event through BioNTech's website, where the recording will be archived for one year following the event. [1]
BioNTech's AI strategy aims to leverage advanced computational techniques to accelerate the development of novel biopharmaceuticals. The company's portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, targeted therapies such as antibody-drug conjugates (ADCs), and innovative chimeric antigen receptor (CAR) T cell therapies. [1]
By showcasing its AI capabilities and applications, BioNTech aims to provide investors and stakeholders with a comprehensive understanding of its innovative approach to drug development. The event is expected to offer valuable insights into the company's strategic direction and the potential impact of AI on the biopharmaceutical industry. [1]
BioNTech SE, a biopharmaceutical company, will host its second AI Day on October 1, 2025, in London. The event will showcase BioNTech's AI strategy and capabilities, as well as its applications in the company's pipeline and internal processes. The live webcast will be available via a link on BioNTech's website, and a recording will be archived for one year.
BioNTech SE, a leading biopharmaceutical company, will host its second AI Day on October 1, 2025, in London. The event, part of BioNTech's "Innovation Series," will focus on the company's artificial intelligence strategy and capabilities, highlighting the applications of AI in its pipeline and internal processes. This event marks a significant milestone in BioNTech's continued focus on AI development, following its acquisition of InstaDeep Ltd. [1]The event will take place at 9:00 AM EDT (3:00 PM CEST) and will be accessible via a live webcast. Participants can also access the slides and a recording of the event through BioNTech's website, where the recording will be archived for one year following the event. [1]
BioNTech's AI strategy aims to leverage advanced computational techniques to accelerate the development of novel biopharmaceuticals. The company's portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, targeted therapies such as antibody-drug conjugates (ADCs), and innovative chimeric antigen receptor (CAR) T cell therapies. [1]
By showcasing its AI capabilities and applications, BioNTech aims to provide investors and stakeholders with a comprehensive understanding of its innovative approach to drug development. The event is expected to offer valuable insights into the company's strategic direction and the potential impact of AI on the biopharmaceutical industry. [1]
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios